Cardiogen

Cardiogen is Ala-Glu-Asp-Arg. Khavinson's group reports that it restores protein-synthetic activity in aged cardiomyocyte cultures and improves markers of myocardial contractility and mitochondrial density in aged rodents. The mechanistic claim is the class-standard one: a small charged peptide reaching the nucleus and de-repressing tissue-specific genes, with the arginine residue proposed to drive the DNA groove interaction. Cardiogen has also been described in Russian sources as improving recovery after myocardial ischaemia, but that work is not available in a form a Western reader can evaluate.

Targets: Cardiomyocytes, Contractile protein synthesis, Myocardial mitochondria

• · Standard vial-market protocol from a 20 mg vial; no dose-finding data exists.
• · Chelohart is the corresponding heart Cytomax capsule if you prefer the extract format.

Work out your exact syringe units →

• commonInjection-site irritation— Transient.
• commonNo consistent systemic side effects reported— Reflects a thin exposure record rather than demonstrated safety.

• Do not substitute this for actual cardiac care - using an unproven peptide in place of guideline heart failure or ischaemic therapy is the real danger with this compound.
• Pregnancy and breastfeeding - no data.
• Active malignancy.

• synergyvesugen — Heart plus vessel is the standard Russian cardiovascular Cytogen pairing.
• synergyss-31 — Both are aimed at cardiac mitochondria, though elamipretide has vastly better evidence and is doing the real work.

• · If you have known cardiac disease, keep to your normal cardiology follow-up - echo, BNP and symptom tracking are the meaningful measures, not anything specific to this peptide.
• · Blood pressure and resting heart rate logged across a course.

Not approved for human use in the US, UK or EU; sold as a research chemical or as a supplement capsule in Russia and Eastern Europe.

• Khavinson & Malinin, Gerontological Aspects of Genome Peptide Regulation (Karger monograph) (review)
• Khavinson, Linkova & Tarnovskaya, short peptides regulate gene expression (preclinical)

Cardiogen has the thinnest verifiable file of the injectable Cytogens, and the two papers I could confirm are not the ones the marketing leans on. Chalisova's group looked at myocardium tissue culture from young and old rats and reported effects on tissue development, comparing the peptide against free amino acids - that is the substrate for the contractile-protein-synthesis claim. The other confirmed paper is stranger and more interesting: Levdik and Knyazkin reported a tumour-modifying effect of cardiogen on M-1 sarcoma in senescent rats. A cardiac peptide with an oncological readout is not what the label suggests, and it is another example of the tissue-specificity doctrine not surviving contact with the primary literature. What I could not verify is anything about mitochondria. The mitochondrial density and myocardial contractility claims that appear throughout vendor copy are not supported by a paper I was able to retrieve, and the arginine-drives-the-DNA-groove-interaction argument is a structural rationalisation from the docking work on the family generally rather than a Cardiogen-specific finding. The honest summary: this is the class mechanism - small charged peptide, no receptor, proposed nuclear entry and chromatin de-repression - applied to heart tissue on the strength of a naming convention and one organotypic culture study.

Substitution, and here it can kill someone. Heart failure and ischaemic heart disease have therapies - ACE inhibitors or ARNIs, beta blockers, SGLT2 inhibitors, mineralocorticoid antagonists - with mortality reductions demonstrated in tens of thousands of randomised patients. Cardiogen has an organotypic rat myocardium culture. Anyone deferring or reducing guideline therapy to run peptide courses is trading proven survival benefit for a naming convention. Second, the mitochondrial claims are unverified: I could not retrieve a study demonstrating mitochondrial density or contractility changes with this peptide, so treat that language as vendor copy. Third, the same microgram-versus-milligram dose gap as the rest of the class.

• Myocardial tissue in organotypic culture — No binding data

  Reported effects on the development of myocardium tissue culture from young and old rats. This is the substrate for the contractile-protein claim and it is a dish.

• M-1 sarcoma in senescent rats

  Reported tumour-modifying effect - an off-label oncological finding that further undermines the idea that these peptides act only on their named tissue.

• No identified receptor — None published

  No receptor. No binding constant. No mitochondrial target I could verify.

Nothing acute and nothing perceptible at any point. Days one to twenty: injection-site irritation only. Weeks four to twelve: if you are tracking blood pressure and resting heart rate properly, this is where a change would show, and no change is the expected result. Anything you feel is either another compound in the stack or expectation. If you develop chest pain, breathlessness or palpitations during a course, that is a cardiac event to be investigated, not a peptide side effect to be waited out.

Cardiogen plus Vesugen is the standard Russian cardiovascular pairing and is convention, not tested synergy. Cardiogen plus Chelohart is duplication - Chelohart is the heart Cytomax extract. The stack that shows up in longevity protocols is with elamipretide (SS-31), and the framing there should be honest: elamipretide is a mitochondria-targeted tetrapeptide with completed clinical trials in primary mitochondrial myopathy and Barth syndrome, real cardiolipin binding, and a defined mechanism. If those two are in a stack together and anything changes, elamipretide is the reason.

Against elamipretide (SS-31): not comparable. Elamipretide binds cardiolipin, has a defined mitochondrial mechanism and has been through registrational trials. Against Vesugen: Vesugen has a more specific in vitro dataset - endothelin-1, connexins, sirtuin-1 - than Cardiogen has for heart tissue. Against Chelohart: the synthetic at least has defined chemistry. Against guideline heart failure therapy: there is no comparison to make, and framing it as one is the mistake that causes harm with this compound.

$35–$110/month. One 20 mg vial per ten- to twenty-day course. Indicative research-chemical pricing, not verified against vendor listings in this session.

• ?The Ala-Glu-Asp-Arg sequence is what the Khavinson literature and vendor material state, but Cardiogen has no PubMed supplementary-concept record giving the sequence, so I could not verify it independently. Flagged as unverified.
• ?No pharmacokinetic data of any kind.
• ?I could not verify any study demonstrating mitochondrial density, mitochondrial function or contractility changes with this peptide despite those claims being standard in vendor material.
• ?No human data of any kind - no trial, no case series, no bloodwork study.
• ?The verified in vivo result is an oncological one in sarcoma-bearing senescent rats, not a cardiac one.
• ?Oral absorption of the intact tetrapeptide has never been demonstrated.
• ?Cost figures are indicative research-chemical estimates and were not verified against live vendor listings in this session.

• Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats Levdik NV, Knyazkin IV, Bulletin of Experimental Biology and Medicine, 2009 · PMID 20396706

  An in vivo result for Cardiogen, though on an oncological endpoint rather than a cardiac one.

• The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats Chalisova NI, Lesniak VV, Balykina NA, et al., Advances in Gerontology, 2009 · PMID 20210190

  The organotypic myocardium culture work - the only cardiac-tissue study for this peptide that I could verify.

• Study of interactions between DNA and tetrapeptides using methods of molecular mechanics Tarnovskaya SI, Yakutseni PP, Khavinson VKh, Bulletin of Experimental Biology and Medicine, 2014 · PMID 24770759

  The tetrapeptide-DNA docking model that the arginine-groove-binding argument is drawn from.

• The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats Zakutskiĭ AN, Chalisova NI, Ryzhak GA, et al., Advances in Gerontology, 2006 · PMID 17152728

  The organotypic-culture basis for the tissue-specificity claim across the synthetic series.